GlassScriptPhysician profile
Christina Lin
NPI 1164884458
$1,582.08
in general payments reported to CMS, 2019-2025
18 companies · $598 in 2025
The $598 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $87.45 · 2021: $225 · 2022: $76.43 · 2023: $106 · 2024: $490 · 2025: $598.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,193.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,193.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $603.51 | 2020-2025 | Wavewriter Alpha Prime 16 |
| Averitas Pharma INC. | $279.49 | 2023-2024 | Qutenza |
| Spr Therapeutics, INC | $228.12 | 2024-2025 | Sprint Pns System |
| Medtronic, INC. | $101.52 | 2021 | |
| Lilly USA, LLC | $68.85 | 2025 | Jardiance |
| Amneal Pharmaceuticals LLC | $54.37 | 2022-2024 | Ongentys |
| Dexcom, INC. | $35.04 | 2025 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $33.87 | 2025 | Tezspire |
| Cleerly, INC. | $29.63 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Madrigal Pharmaceuticals | $24.41 | 2025 | Rezdiffra |
| Verona Pharma, INC. | $21.35 | 2025 | Ohtuvayre |
| Pfizer INC. | $19.82 | 2025 | |
| Alexion Pharmaceuticals, INC. | $17.32 | 2025 | Strensiq |
| Abbvie INC. | $15.67 | 2025 | |
| Capsovision, INC. | $15.37 | 2024 | Capsocam Plus |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stimwave Technologies Incorporated | $15.32 | 2021 | |
| Cequr Corporation | $13.26 | 2025 | Cequr Simplicity |
| Dynavax Technologies Corporation | $5.16 | 2025 | Heplisav-B |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christina Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.